Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
Hebrew University of Jerusalem · Hadassah Medical Center · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
672
total citations
- FWCI
- 64.66
- Percentile
- 100%
- References
- 29
Citations per year
Authors
21- OMOfri MosenzonCorresponding
Hebrew University of Jerusalem, Hadassah Medical Center
- SDStephen D. Wiviott
Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group
- ACAvivit Cahn
Hebrew University of Jerusalem, Hadassah Medical Center
- ARAliza Rozenberg
Hebrew University of Jerusalem, Hadassah Medical Center
- IYIlan Yanuv
Hebrew University of Jerusalem, Hadassah Medical Center
Topics & keywords
Topics
Keywords
- Medicine
- Dapagliflozin
- Renal function
- Type 2 diabetes
- Internal medicine
- Kidney disease
- TIMI
- Dialysis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- MCMayo Clinic
- ALAbbott Laboratories
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- AAstraZeneca
- BBayer
- GGlaxoSmithKline
- MMerck
- NNovartis
- SSanofi
- ACAmerican College of Cardiology Foundation
- GSGilead Sciences
- ISIcahn School of Medicine at Mount Sinai
- CCCleveland Clinic
- BIBoehringer Ingelheim
- TPTakeda Pharmaceutical Company
- BSBoston Scientific Corporation
- BVBoston VA Research Institute
- ACAmarin Corporation
- SFSociety for Academic Continuing Medical Education
- MCMedicines Company
- MMyoKardia
- RBRegado Biosciences
- DFDeutsche ForschungsgemeinschaftAwards: 1109/1-1, ZE 1109/1-1, ZE 1109/1–1
- DDaiichi-Sankyo
- EEisai
- MMedImmune
- BBiotronik
- SJSt. Jude Medical
- JRJanssen Research and Development
- DCDuke Clinical Research Institute